Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 1 |
2014 | 1 |
2021 | 2 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2193119. doi: 10.1080/21645515.2023.2193119. Epub 2023 Apr 14.
Hum Vaccin Immunother. 2023.
PMID: 37057755
Free PMC article.
Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects.
Peterson J, Van Twuijver E, Versage E, Hohenboken M.
Peterson J, et al. Among authors: van twuijver e.
Vaccines (Basel). 2022 Mar 23;10(4):497. doi: 10.3390/vaccines10040497.
Vaccines (Basel). 2022.
PMID: 35455245
Free PMC article.
Item in Clipboard
Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
Chanthavanich P, Versage E, Van Twuijver E, Hohenboken M.
Chanthavanich P, et al. Among authors: van twuijver e.
Vaccine. 2021 Nov 16;39(47):6930-6935. doi: 10.1016/j.vaccine.2021.10.010. Epub 2021 Oct 25.
Vaccine. 2021.
PMID: 34711436
Free article.
Clinical Trial.
Item in Clipboard
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults.
Versage E, van Twuijver E, Jansen W, Theeuwes A, Sawlwin D, Hohenboken M.
Versage E, et al. Among authors: van twuijver e.
Vaccines (Basel). 2021 Dec 11;9(12):1468. doi: 10.3390/vaccines9121468.
Vaccines (Basel). 2021.
PMID: 34960214
Free PMC article.
Item in Clipboard
Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation.
Pfaar O, van Twuijver E, Hecker H, Boot JD, van Ree R, Klimek L.
Pfaar O, et al. Among authors: van twuijver e.
Int Arch Allergy Immunol. 2013;160(4):420-4. doi: 10.1159/000343026. Epub 2012 Nov 23.
Int Arch Allergy Immunol. 2013.
PMID: 23183541
Clinical Trial.
Item in Clipboard
A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations.
Klimek L, Sperl A, van Twuijver E, van Ree R, Kleinjans H, Boot JD, Pfaar O.
Klimek L, et al. Among authors: van twuijver e.
Clin Transl Allergy. 2014 Jul 23;4:23. doi: 10.1186/2045-7022-4-23. eCollection 2014.
Clin Transl Allergy. 2014.
PMID: 25097754
Free PMC article.
Item in Clipboard
Cite
Cite